222 related articles for article (PubMed ID: 10468021)
1. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
Polli JW; Jarrett JL; Studenberg SD; Humphreys JE; Dennis SW; Brouwer KR; Woolley JL
Pharm Res; 1999 Aug; 16(8):1206-12. PubMed ID: 10468021
[TBL] [Abstract][Full Text] [Related]
2. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
3. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
5. Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography.
Solon EG; Balani SK; Luo G; Yang TJ; Haines PJ; Wang L; Demond T; Diamond S; Christ DD; Gan LS; Lee FW
Drug Metab Dispos; 2002 Nov; 30(11):1164-9. PubMed ID: 12386120
[TBL] [Abstract][Full Text] [Related]
6. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.
Edwards JE; Brouwer KR; McNamara PJ
Antimicrob Agents Chemother; 2002 Jul; 46(7):2284-6. PubMed ID: 12069991
[TBL] [Abstract][Full Text] [Related]
7. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
8. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
9. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
10. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Wire MB; Shelton MJ; Studenberg S
Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
[TBL] [Abstract][Full Text] [Related]
11. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
[TBL] [Abstract][Full Text] [Related]
12. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
13. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells.
Woodahl EL; Yang Z; Bui T; Shen DD; Ho RJ
AIDS; 2005 Oct; 19(15):1617-25. PubMed ID: 16184031
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology and pharmacokinetics of amprenavir.
Sadler BM; Stein DS
Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
[TBL] [Abstract][Full Text] [Related]
15. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
Drewe J; Gutmann H; Fricker G; Török M; Beglinger C; Huwyler J
Biochem Pharmacol; 1999 May; 57(10):1147-52. PubMed ID: 11230802
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
[TBL] [Abstract][Full Text] [Related]
17. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
Schmidt B; Korn K; Moschik B; Paatz C; Uberla K; Walter H
Antimicrob Agents Chemother; 2000 Nov; 44(11):3213-6. PubMed ID: 11036057
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.
Yu L; Bridgers A; Polli J; Vickers A; Long S; Roy A; Winnike R; Coffin M
Pharm Res; 1999 Dec; 16(12):1812-7. PubMed ID: 10644067
[TBL] [Abstract][Full Text] [Related]
19. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
20. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
Holmstock N; Annaert P; Augustijns P
Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
